![](/images/graphics-bg.png)
Spironolactone in chronic hemodialysis patients improves cardiac function
المؤلفون المشاركون
Shahidi, Shahrzad
Taheri, Shahram
Mortazavi, Mojhgan
Pourmoghadas, Ali
Garakyaraghi, Muhammad
Seirafian, Shiva
Eshaghian, Afrooz
Ghassami, Maryam
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 20، العدد 3 (30 يونيو/حزيران 2009)، ص ص. 392-397، 6ص.
الناشر
تاريخ النشر
2009-06-30
دولة النشر
السعودية
عدد الصفحات
6
التخصصات الرئيسية
الموضوعات
الملخص EN
We performed this study to assess whether low dose spironolactone could be administered in hemodialysis (HD) patients with moderate to severe heart failure to improve cardiovascular function and reduce hospitalization without inducing hyperkalemia.
We enrolled 16 chronic HD patients with moderate to severe heart failure and left ventricle ejection fraction : 5 45%.
In a double blinded randomized placebo controlled study, one group of 8 patients received 25 mg of spironolactone after each dialysis session within six months, and the rest received a placebo.
Echocardiography was performed on all the patients to assess ejection fraction and left ventricular mass during 12 hours after completion of hemodialysis at the beginning and the end of study.
Serum potassium was measured predialysis every 4 weeks.
The mean ejection fraction increased significantly more in spironolactone group during the study period than in the placebo group (6.2 ± 1.64 vs.
0.83 ± 4.9, P = 0.046).
The mean left ventricular mass decreased in the spironolactone group, but increased significantly in the placebo group during the period (-8.4 ± 4.72 vs.
3 ± 7.97.
95%, P = 0.021).
The incidence of hyperkalemia was not significantly increased in the study or controlled groups.
In conclusion, we found in this study that administration of spironolactone in chronic HD patients with moderate to severe heart failure substantially improved their cardiac function and decreases left ventricular mass without development of significant hyperkalemia.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Taheri, Shahram& Mortazavi, Mojhgan& Shahidi, Shahrzad& Pourmoghadas, Ali& Garakyaraghi, Muhammad& Seirafian, Shiva…[et al.]. 2009. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation،Vol. 20, no. 3, pp.392-397.
https://search.emarefa.net/detail/BIM-36688
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Taheri, Shahram…[et al.]. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation Vol. 20, no. 3 (Sep. 2009), pp.392-397.
https://search.emarefa.net/detail/BIM-36688
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Taheri, Shahram& Mortazavi, Mojhgan& Shahidi, Shahrzad& Pourmoghadas, Ali& Garakyaraghi, Muhammad& Seirafian, Shiva…[et al.]. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi Journal of Kidney Diseases and Transplantation. 2009. Vol. 20, no. 3, pp.392-397.
https://search.emarefa.net/detail/BIM-36688
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 396-397
رقم السجل
BIM-36688
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)